The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Interim results from DESTINY-Lung01: T-DXd in HER2-overexpressing NSCLC
Kazuhiko Nakagawa, MD, PhD, Kindai University Hospital, Osaka, Japan, shares interim results from the HER2-overexpressing cohort of the DESTINY-Lung01 trial (NCT03505710), investigating trastuzumab deruxtecan (T-DXd) in non-small cell lung cancer (NSCLC). T-DXd is a novel HER2-targeted antibody-drug conjugate under investigation in two cohorts in the Phase II DESTINY trial: patients overexpressing HER2 and patients with a HER2-activating mutation. The interim data for the HER2-overexpressing cohort shows T-DXd to be efficacious, with an overall response rate of 24.5% and a disease control rate of 69.4%. Treatment-emergent adverse events caused dose interruption in 53.1% discontinuation in 22.4%. An additional evaluation of a lower dose T-DXd has begun enrollment to further characterize the treatment’s safety and efficacy profile. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
